The new research has made strides in understanding the mechanism behind a type of dementia that affects young people.
New research offers insight into the basic biology of frontotemporal dementia caused by a particular genetic mutation.
At a glance:
- New findings offer insight into the basic biology of frontotemporal dementia, a devastating neurodegenerative disorder caused by a specific genetic mutation.
- Researchers revealed that a genetic form of frontotemporal dementia is connected with abnormal lipid accumulation in the brain, which is caused by disrupted cell metabolism.
- The research reveals a fundamental component of the process that leads to frontotemporal dementia, and the results may aid in the development of targeted treatments.
Around 55 million individuals worldwide are affected by dementia, a group of neurodegenerative conditions that cause memory loss and cognitive impairments. Nevertheless, despite its widespread occurrence, there are few effective treatments, in part because researchers are still unsure of the precise molecular and cellular causes of dementia.
Researchers from Harvard Medical School and Harvard T. H. Chan School of Public Health are leading a team that has made progress in comprehending the mechanism behind a type of dementia that strikes early in life.
Researchers found that a genetic form of frontotemporal dementia (FTD) is linked to the accumulation of certain lipids in the brain and that this accumulation is caused by a protein deficiency that disrupts cell metabolism. The findings were recently published in the journal Nature CommunicationsNature Communications is a peer-reviewed, open access, multidisciplinary, scientific journal published by Nature Research. It covers the natural sciences, including physics, biology, chemistry, medicine, and earth sciences. It began publishing in 2010 and has editorial offices in London, Berlin, New York City, and Shanghai. ” data-gt-translate-attributes=”[{“attribute”:”data-cmtooltip”, “format”:”html”}]”>Nature Communications.
The findings, which are based on experiments in both animal models and human brain cells, provide new insights into FTD that may guide the development of new treatments. Furthermore, the findings highlight a metabolic disruption mechanism that may be significant in other types of neurodegeneration, according to the researchers.
A Black Box
There are several different types of dementia, each with complicated genetics that involve various mutations. FTD, characterized by a loss of cells in the frontal and temporal lobes of the brain, accounts for 5 to 10 percent of dementia cases. Often diagnosed in patients between 45 and 65 years old, the genetic forms tend to cluster in families. Around 15 percent of the time, FTD is linked to a specific mutation in the GRN gene, which causes brain cells to stop making a protein called progranulin.
Previous studies have linked progranulin to parts of the cell called lysosomes, which are responsible for cleanup and other metabolic activities in cells. However, “the function of the protein, including its role in the lysosome, has remained sort of a black box,” said co-senior author Wade Harper, the Bert and Natalie Vallee Professor of Molecular Pathology in the Department of Cell Biology in the Blavatnik Institute at HMS.
Harper collaborated on the study with co-senior authors Tobias Walther and Robert Farese Jr., who were professors of cell biology at HMS and professors of molecular metabolism at Harvard Chan School when they conducted the research, as well as lead authors Sebastian Boland, a former research fellow in the Farese & Walther Lab, and Sharan Swarup, a former research fellow in the Harper lab.
The researchers initially found that progranulin-deficient human cell lines and mouse brains, as well as brain cells from patients with FTD, had an accumulation of gangliosides — lipids commonly found throughout the nervous system.
Next, the team used recently developed technology for purifying lysosomes to analyze the types and amounts of proteins and lipids present inside them. Using this technique, the scientists found that lysosomes in these cells and tissues from brains with FTD had reduced levels of progranulin, as well as lower-than-normal levels of a lipid called BMP, which is required to break down gangliosides, the lipids commonly found in the central nervous system. However, when researchers added BMP to cells, they observed that these cells accumulated far lower levels of gangliosides.
Together, the findings suggest that progranulin in lysosomes helps maintain the BMP levels needed to prevent gangliosides from accumulating in brain cells — buildup that may contribute to FTD.
“We’ve uncovered a role for progranulin in supporting proper degradation of gangliosides,” while also showing that it may be possible to correct the problem, Farese said.
“People are already working on treatments that involve giving patients a source of progranulin, and our results are consistent with that approach potentially being therapeutically beneficial,” Walther added. Moreover, it may be possible to develop therapies that focus on replacing BMP rather than progranulin, he said, and thus target a different part of the mechanism.
The researchers also think that a similar lysosome-based mechanism could be relevant for neurodegenerative diseases beyond FTD — an idea that they note is rapidly gaining ground in the field.
“The lysosome may be a key feature of many kinds of neurodegenerative diseases — but these diseases likely all connect with the lysosome in different ways,” Harper said. For example, scientists already know that a protein implicated in a genetic form of Parkinson’s disease controls aspects of lysosomal function. More research is needed, Farese added, to understand precisely how various lipids and proteins interact with lysosomes within the context of different neurodegenerative diseases.
Now, the researchers are studying several genes linked with lysosomal function, including genes associated with lysosomal storage diseases, to find connections between them. A central remaining question is how progranulin elevates BMP levels in the brain. Additional studies are needed to further elucidate the steps of the mechanism the team uncovered and to explain how lipid accumulation translates into cognitive decline.
“This study demonstrates the power of collaboration and following the science,” Walther said. “By using the right tools and asking the right detailed questions, you can sometimes uncover things that are unexpected.”
Reference: “Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis” by Sebastian Boland, Sharan Swarup, Yohannes A. Ambaw, Pedro C. Malia, Ruth C. Richards, Alexander W. Fischer, Shubham Singh, Geetika Aggarwal, Salvatore Spina, Alissa L. Nana, Lea T. Grinberg, William W. Seeley, Michal A. Surma, Christian Klose, Joao A. Paulo, Andrew D. Nguyen, J. Wade Harper, Tobias C. Walther and Robert V. Farese Jr., 7 October 2022, Nature Communications.
DOI: 10.1038/s41467-022-33500-9
The study was funded by the Bluefield Project to Cure FTD, the National Institutes of Health, Google Ventures, Third Rock Ventures, the Aligning Science Across Parkinson’s initiative, the Canadian Institutes of Health Research, and the Howard Hughes Medical Institute.
Disclosures: Wade Harper is a founder and scientific advisory board member of Caraway Therapeutics Inc. and a founding scientific board member of Interline Therapeutics Inc. Robert Farese Jr. serves gratis on the board of the Bluefield Project to Cure FTD. Tobias Walther is a founder and scientific advisory board chair of Antora Bio Inc.
Source: SciTechDaily
